Gadolinium
- Generic Name
- Gadolinium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Gd
- CAS Number
- 7440-54-2
- Unique Ingredient Identifier
- AU0V1LM3JT
- Background
Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Molecular Trap Boosts Diagnostics, Speeds Drug Development
IOCB Prague scientists, led by Dr. Miloslav Polášek, developed compounds up to a million times more stable than current medical substances, using a new 'ClickZip' synthetic principle to irreversibly bind lanthanides in drug molecules, enhancing safety and stability, with potential applications in medicine and industry.
GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese
GE HealthCare's Phase I clinical trial of a novel manganese-based MRI contrast agent showed it was well tolerated with no serious adverse events, potentially offering an alternative to gadolinium-based agents and addressing environmental concerns.
MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma
MTX110, a water-soluble panobinostat formulation, showed updated PFS and OS data in the MAGIC-G1 phase 1 study for recurrent glioblastoma, with 2 patients achieving OS of 12 and 13 months. MTX110 is delivered directly to the tumor via convection-enhanced delivery, bypassing the blood-brain barrier. The study aims to identify the recommended phase 2 dose and assess safety, OS, PFS, and response rate.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath